Last reviewed · How we verify
NCT03652493: PRO-CARBO
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
Phase 2 trial testing Carboplatin in Castration-resistant Prostate Cancer in 16 participants. Completed in 21 May 2021.
27 April 2021
Quick facts
| Lead sponsor | Centre Francois Baclesse |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 10 September 2018 |
| Primary completion | 27 April 2021 |
| Estimated completion | 21 May 2021 |
| Sites | 4 locations across France |
Drugs / interventions tested
- Carboplatin (Carboplatin) — full drug profile →
Conditions studied
- Castration-resistant Prostate Cancer — all drugs for Castration-resistant Prostate Cancer →
- Metastasis — all drugs for Metastasis →
Sponsor
Centre Francois Baclesse — full company profile →
Who can join
18 and older, male only, with Castration-resistant Prostate Cancer or Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators propose a phase II study to evaluate the efficacy of carboplatin monotherapy in the tumor subgroup of metastatic castration-resistant prostatic carcinomas with somatic abnormality in the Homologous Recombination (HR) pathway. This study may also better characterize the molecular abnormalities of tumors required for the carboplatin response
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
Lozano R, Castro E, Aragón IM, Cendón Y, et al · · 2021 · cited 81× · PMID 33106584 · DOI 10.1038/s41416-020-01114-x -
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Slootbeek PHJ, Duizer ML, van der Doelen MJ, Kloots ISH, et al · · 2021 · cited 30× · PMID 32965028 · DOI 10.1002/ijc.33306 -
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
Leman R, Muller E, Legros A, Goardon N, et al · · 2023 · cited 21× · PMID 37756555 · DOI 10.1158/1078-0432.ccr-23-0898 -
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.
Coquan E, Penel N, Lequesne J, Leman R, et al · · 2024 · cited 2× · PMID 38425504 · DOI 10.1177/17562872241229876
Verify or expand the search:
- PubMed search for NCT03652493
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Carboplatin
Trials testing the same drug.
- NCT04832438 — 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma · Phase 2 · withdrawn
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
Other recruiting trials for Castration-resistant Prostate Cancer
Currently open trials in the same condition.
- NCT07259213 — A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC · Phase 1, PHASE2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT06636123 — GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy · Phase 1 · recruiting
- NCT06378866 — Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivati · Phase 2 · recruiting
- NCT06585007 — Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer · Phase 3 · recruiting
Other Centre Francois Baclesse trials
Trials by the same sponsor.
- NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
- NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
- NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
- NCT06612827 — Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions · recruiting
- NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03652493 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
- Last refreshed: 6 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03652493.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing